药物类型 单克隆抗体 |
别名 AZD 8895、AZD-8895、AZD8895 |
作用机制 SARS-CoV-2 S protein抑制剂(冠状病毒刺突糖蛋白抑制剂) |
治疗领域- |
在研适应症- |
非在研适应症- |
原研机构 |
在研机构- |
非在研机构- |
最高研发阶段- |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
N/A | 44 | 構艱餘窪製遞顧餘膚顧(膚鏇顧範窪艱積鹹繭網) = 選鏇醖選製淵觸繭鏇齋 蓋積繭製獵鏇鹹獵顧襯 (艱衊願鏇鏇選鑰淵繭襯 ) | - | 2023-09-26 | |||
N/A | 55 | Tixagevimab/cilgavimab (Evusheld) | 遞餘醖膚鬱鑰壓鹽鑰淵(蓋積廠淵遞餘鹹築醖艱) = Overall, 5 patients (9%) were diagnosed with COVID-19 at a median of 1 month (range 1-2) after receiving tixagevimab/cilgavimab. All of these patients received nirmatrelvir/ritonavir (Paxlovid) for 5 days as outpatients along with supportive care as per standard clinical practice and recovered completely. There were no COVID-19-related hospitalization or deaths. 憲廠蓋積繭壓遞獵選憲 (選築壓繭鏇鹹齋鏇觸築 ) 更多 | - | 2023-09-26 | ||
N/A | 21 | Tixagevimab and Cilgavimab (TGM/CGM) | 夢觸膚顧獵簾鹹構網簾(夢艱衊鹹衊觸構廠選齋) = no COVID-19 related symptoms were observed in the month of follow-up after TGM/CGM administration 齋壓壓獵獵淵積憲鏇衊 (糧觸糧範蓋鹽網鹽艱鏇 ) 更多 | - | 2023-05-31 | ||
N/A | - | 選選醖鬱齋壓網鏇範淵(廠構鏇衊繭衊醖艱夢鬱) = Breakthrough infections on tixagevimab/cilgavimab occurred in 4 cases (8%), 3 of which occurred in patients receiving medications suppressing B and T lymphocyte proliferation (two cases on mycophenolate mofetil, and one case with prior history of cyclophosphamide and mitoxantrone treatment) 網築淵範艱淵鹽餘夢鏇 (襯築壓築願憲憲積膚願 ) | - | 2023-05-30 | |||
N/A | 348 | 襯蓋鹽獵淵餘觸鏇壓齋(範獵築鏇艱壓淵積憲襯) = 3 of which occurred in patients receiving medications suppressing B and T lymphocyte proliferation (two cases on mycophenolate mofetil, and one case with prior history of cyclophosphamide and mitoxantrone treatment) 遞鏇網壓鹹範築淵鹹醖 (鬱觸製製鬱鏇壓遞選壓 ) | - | 2023-04-25 | |||
N/A | - | - | CAR-T-cell recipients | 廠鹹蓋蓋範齋艱鹹網鏇(築範醖鑰憲觸糧廠顧鹽) = No patients reported adverse events from drug administration 鏇獵衊製鹹簾糧廠鏇鑰 (網衊簾願遞憲鏇衊網糧 ) | - | 2023-04-23 | |
HSCT recipients |